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Several members of the nuclear receptor family, in-
cluding glucocorticoid receptor (GR), retinoic acid re-
ceptor (RAR), thyroid hormone receptor (T3R), vitamin DSummary
receptor, and retinoid X receptor (RXR) (reviewed by
Beato et al., 1995), have been reported to inhibit AP-1Nuclear receptors regulate gene expression by direct
activity (Jonat et al., 1990; Yang-Yen et al., 1990; SchuÈ leactivation of target genes and inhibition of AP-1. Here
et al., 1990; Lucibello et al., 1990; Tzukerman et al., 1991;we report that, unexpectedly, activation by nuclear
Salbert et al., 1993) without inhibition of DNA binding inreceptors requires the actions of CREB-binding pro-
vivo (KoÈ nig et al., 1992). AP-1 activity is mediated bytein (CBP) and that inhibition of AP-1 activity is the
activation of various heterodimers, particularly Jun andapparent result of competition for limiting amounts
Fos or related proteins (reviewed by Abate and Curran,of CBP/p300 in cells. Utilizing distinct domains, CBP
1990; Angel and Karin, 1991), involving molecular mech-directly interacts with the ligand-binding domain of
anisms similar to that involved in regulating the cAMPmultiple nuclear receptors and with the p160 nuclear
response element±binding protein (CREB) (Arias et al.,receptor coactivators, which upon cloning have proven
1994). CREB functions as a homodimer, in many casesto be variants of the SRC-1 protein. Because CBP
requiring phosphorylation of Ser-133 in the kinase-represents a common factor, required in addition to
inducible domain to serve as a transactivator (Gonzalezdistinct coactivators for function of nuclear receptors,
et al., 1991). These observations prompted an expres-CREB, and AP-1, we suggest that CBP/p300 serves as
sion screening approach that identified a 265 kDaan integrator of multiple signal transduction pathways
CREB-binding protein, referred to as CBP, that inter-within the nucleus.
acted strongly with phosphorylated CREB (Chrivia et
al., 1993; Kwok et al., 1994). A protein highly related
to CBP, p300, was independently identified based onIntroduction
interactions with ElA (Eckner et al., 1994). These two
proteins share extensive regions of homology through-
Nuclear receptors are ligand-dependent transcription
out, including regions of interaction with CREB (Chrivia
factors that regulate diverseaspects of growth, develop-
et al., 1993), E1A (Lundblad et al., 1995; Arany et al.,
ment, and homeostasis by binding as homodimers or 1995), TFIIB (Kwok et al., 1994), and c-Fos (Bannister
heterodimers to their cognate DNA elements (Yu et al.,
and Kouzarides, 1995), as well as a bromodomain (Arany
1991; Bugge et al., 1992; Kliewer et al., 1992; Leid et al.,
et al., 1994). Several independent approaches, involving
1992; Marks et al., 1992; Zhang et al., 1992; Chambon,
cotransfection assays or microinjection of anti-CBP an-
1994; Tsai and O'Malley, 1994; Beato et al., 1995; tibody and reporter, have revealed that CBP is required
Mangelsdorf et al., 1995). Transactivation by nuclear for activation of both CREB and AP-1 (Kwok et al., 1994;
receptors depends ona conservedmotif within thedistal Arias et al., 1994).
C-terminus, referred to as the AF2 domain. Several lines In this paper, we demonstrate that the ligand-binding
of evidence indicate that nuclear receptors must interact domains of multiple nuclear receptors, including RAR
with additional factors dependent on a conserved distal and GR, interact strongly in the cell with a conserved
C-terminal motif (AF2) to mediate both activation and domain in the N-terminus of CBP and p300 in a ligand-
repression of gene expression (Cavailles et al., 1994; dependent manner. Further, the putative coactivator
Halachmi et al., 1994; Baniahmad et al., 1995; HoÈ rlein p160 was found to interact independently and specifi-
et al., 1995; Chen and Evans, 1995; Kurokawa et al., cally with a conserved C-terminal domain in CBP and
1995). Biochemical assays have identified 140 and 160 p300. Expression cloning of p160 cDNAs based on nu-
kDa proteins (p140 and p160) (Halachmi et al., 1994; clear receptor and CBP interaction surprisingly revealed
their identity as variants of SRC-1. Several independent
experimental approaches have suggested a central role6The contributions of these authors are to be considered equivalent.
for CBP in ligand-dependent activation of RAR and T3R,7 Present address: Institute of Molecular and Cellular Biology, Na-
tional University of Singapore, Singapore 0511. comparable to its role for CREB and Jun/Fos. Our data
Cell
404
indicate competition for limiting amounts of CBP may functions of nuclear receptors. Although CBP is widely
account for many of the inhibitory actions of both GR expressed, its low levels are rate limiting for CREB-
and RAR on AP-1 activation. We propose that CBP/p300 mediated transcription, which permitted cotransfection
is a required component common to the coactivator assays to evaluate a role for CBP in CREB-dependent
complexes of diverse transcription factors, eachutilizing transcription (Kwok et al., 1994). We therefore examined
specific additional coactivators, thus providing a mech- ligand-dependent transcription from a retinoic acid re-
anism for integrating in the nucleus diverse signaling sponse element (RARE) containing promoter in the pres-
pathways in the maintenance of homeostasis. ence and absence of coexpressed CBP. Expression of
CBP led to a 3-fold further enhancement of retinoic
Results acid±dependent transcription, but had little or no effect
on promoters lacking a RARE (Figure 2A). To acquire
Nuclear Receptors Directly Interact with CBP further, independent evidence for a potential role of CBP
To investigate possible direct interactions between nu- in RAR-mediated transcription, we performed in vitro
clear receptors and CBP, a series of overlapping frag- transcription assays using nuclear extracts prepared
ments of the 265 kDa CBP protein were bacterially from cells with varied levels of CBP. To be certain that
expressed as glutathione S-transferase (GST) fusion the effects of CBP were exerted through the ligand-
proteins and tested for interaction with RAR, revealing binding domain of nuclear receptors, we utilized a
a strong ligand-dependent interaction confined to a sin- GAL4±T3 receptor fusion protein (Baniahmad et al.,
gle N-terminal CBP region (Figure 1A). The ability of this 1995). The ability of this fusion protein to activate the
interaction to occur in intact cells in a ligand-dependent tk promoter±containing GAL4-binding elements (17-mer
manner was confirmed using the yeast two-hybrid sys- upstream activating sequence [UAS]) was assessed us-
tem (Figure 1B). Further mapping revealed that the ing GAL4 protein as a control. T3-induced transcription
N-terminal 100 amino acids of CBP retained full interac- of this UAS-driven reporter was increased >5-fold by
tion with RAR; attempts to subdivide further this region additional CBP, while altered levels of CBP had little
resulted in a complete loss of the capacity to interact. effect on transcription of several control promoters (Fig-
Consistent with the ability of several nuclear receptors ure 2B). Increased levels of CBP also markedly in-
to inhibit the activated AP-1 transcriptional response,
creased AP-1 site-dependent reporter expression,
we found that estrogen receptor (ER), T3R, and RXR also consistent with the proposed role of CBP in AP-1 trans-
exhibited strong ligand-dependent interactions with the
activation events (Arias et al., 1994) and indicating that
identical N-terminal domain of CBP, dependent upon a
CBP is limiting in extracts used in in vitro transcription
functional AF2 domain (Figure 1C). Intriguingly, a point
assays.
mutation outside of the AF2domain that conferred domi-
Based on these suggestive results, the role of CBP,nant-negative functions to the RAR (Gly-303→Glu) (Sai-
or highly related factors, in ligand-dependent transcrip-tou et al., 1994) also abolished interactions with CBP
tional activation was directly tested by evaluating the(Figure 1C). Together, these data indicate that CBP
ability of microinjected anti-CBP immunoglobulin Gbinds to the C-terminal domain of ligand-occupied nu-
(IgG) to inhibit ligand-dependent transcription fromclear receptors. These interactions were demonstrated
RARE-containing promoters in intact cells. In each ex-to occur on DNA using the protein-dependent gel mobil-
periment, >200 cells were injected with lacZ reporterity shift assay, in which addition of an N-terminal frag-
plasmids and either control or anti-CBP IgG; cells werement of CBP (amino acids 1±450) caused a marked su-
treated with all-trans retinoic acid and stained withpershift of the RAR±RXR±DNA complex only in the
X-Gal, and positive cells were counted. In these assays,presence of ligand (Figure 1D). The specificity of this
addition of a ligand was required for effective expressioninteraction was established because the region of CBP
of two independent RARE-dependent reporters, but didinteracting with phosphorylated CREB (amino acids
not affect other promoters not containing RAREs (Figure450±720) failed to supershift RAR±RXR±DNA complexes
2C). In three independent experiments, coinjection of(Figure 1D).
increasing concentrations of anti-CBP IgG, but not con-To determine whether complexes between RAR and
trol IgG, resulted in a progressive and specific decreasethe CBP holoprotein occurred in thecontext of the intact
in ligand-dependent gene activation, producing >80%cell, a vector encoding CBP with a C-terminal FLAG
inhibition of ligand-induced activation. Even in the re-epitope was constructed and expressed in a variety of
maining 20% of cells that scored positive, there wascell types. Potential complexes were immunoprecipi-
often a reduced signal compared with levels in cellstated using RAR-specific antisera, fractionated on SDS±
injected with control IgG. These data revealed that, inpolyacrylamide gels, and analyzed by Western blot us-
a concentration-dependent fashion, anti-CBP IgG spe-ing specific monoclonal anti-FLAG antibodies. These
cifically inhibited ligand-dependent activation of tran-assays established that ligand-dependent interactions
scription units containing RAREs, without altering ex-between RAR and CBP occurred in vivo (Figure 1E).
pression of other promoters.Furthermore, specific in vivo interactions with GR and
RXR were demonstrated (Figure 1E).
The Nuclear Receptor±Associated p160
Coactivator Directly Interacts with CBPCBP Modulates Ligand-Dependent
Because CBP or its related family members (or both)Transcriptional Activation
were required for transactivation by retinoic acid andBased on the in vivo interaction between the nuclear
other nuclear receptors, we investigated the possibilityreceptors and CBP, it became of interest to evaluate the
potential role of these interactions in ligand-dependent that putative nuclear receptor coactivators p140 or p160
CBP Integrator Complex in Nuclear Receptor Action
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Figure 1. Ligand-Dependent Interactionsbe-
tween CBP and Nuclear Receptors In Vivo
and In Vitro
(A) Specific regions of CBP interact with li-
ganded RAR and ER C-terminal domains. A
series of GST±CBP fusion proteins encom-
passing the entire CBP protein or GST alone
were subjected to SDS±PAGE, transferred to
nitrocellulose, and tested for their ability to
interact with 32P-labeled ER C-terminus in the
absence or presence of 1026 M b-estradiol.
Equal amounts of protein were loaded. The
arrow indicates the CBP fragment that inter-
acts with ER.
(B) The yeast two-hybrid system reveals that
CBPcontains a domain that specifically inter-
acts with RAR in the presence of ligand (1027
M TTNPB). Fragments encompassing the en-
tire CBP protein were used to generate in-
frame fusions with the B42 activation domain.
LexA human RARa (amino acids 143±462)
was used as a bait. b-Galactosidase activity
was assayed from Saccharomycescerevisiae
(EGY48) containing the pSH18-34 reporter
plasmid to assess in vivo interactions (Gyuris
et al., 1993).
(C) Several members of the nuclear receptor
gene family interact with CBP in the yeast
two-hybrid system. CBP N-terminus (amino
acids 1±450) was used as a prey. Interaction
of LexA fusion proteins encompassing the
C-terminal ligand-binding domains of T3R,
RXR, RAR, and ER was measured in the pres-
ence or absence of the appropriate ligands.
T3R Glu-403→Gln contains a mutation in the
AF2 region. RAR D403 has a C-terminal dele-
tion at amino acid 403 of RARa (Damm et
al., 1993). RAR Gly-303→Glu is a dominant-
negative mutation (Saitou et al., 1994), and
RXR Glu-454→Gln contains a mutation in the
AF2 region that renders it incapable of gene
activation. b-Galactosidase activity was de-
termined as described above. Ligands used
were TRIAC (1027 M) for T3R, TTNPB (1027 M)
for RAR, LG69 (1027 M) for RXR, and
b-estradiol (1027 M) for ER.
(D) CBP exhibits ligand-dependent interac-
tion with RAR±RXR heterodimers on DNA. In-
teraction on DNA was assessed using a
32P-labeled synthetic oligonucleotide encom-
passing the b-RARE and bacterially expressed, purified CBP N-terminus (amino acids 1±450). Brackets indicate RAR±RXR-bound DNA and
the CBP±RAR±RXR±DNA complex. No mobility perturbation was observed using a comparable amount of the CREB-binding domain of CBP
(amino acids 450±720). Efficacy of the CREB-binding domain of CBP was confirmed by its ability to bind protein kinase A±phosphorylated,
but not unphosphorylated, CREB.
(E) Ligand-dependent interactions between CBP and nuclear receptors in the intact cell. FLAG-tagged CBP was expressed by transient
transfection in 293 cells. Anti-RAR, RXR, or GR antisera were used for immunoprecipitation of whole-cell extracts prepared from these cells
in the presence or absence of 1027 M all-trans retinoic acid, 9-cis retinoic acid, or dexamethasone (DEX). Coimmunoprecipitation of CBP was
examined by Western blot analysis using anti-FLAG antibody. The arrows indicate FLAG±CBP. Note that only full-length CBP, containing the
N-terminal nuclear receptor interaction domain, but not the breakdown products, is coimmunoprecipitated.
could themselves interact with CBP. A series of GST identified between the C-terminal region of CBP and
p160 (Figure 3A), but not with p140. These regions arefusion proteins spanning the entire sequence of CBP
were used in interaction assays with extracts from distinct from the internal regions of CBP that interact
with CREB, Fos, TFIIB, and E1A (Chrivia et al., 1993;various cell types. Proteins interacting with CBP frag-
ments were fractionated by SDS±polyacrylamide gel Kwok et al., 1994; Arany et al., 1995; Bannister and
Kouzarides, 1995; Lundblad et al., 1995). To define bet-electrophoresis (SDS±PAGE), transferred to nitrocellu-
lose membranes, and detected using 32P-labeled ER ter the determinants of p160 interaction, a series of frag-
ments were generated from the CBP C-terminus, reveal-C-terminus in the presence of ligand. As expected, the
N-terminal fragment of CBP interacted directly with nu- ing a region of 105 amino acids that was sufficient for
interactions with p160 (Figure 3A).clear receptors. In addition, a specific interaction was
Cell
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Figure 2. Role of CBP in RAR and T3R Gene
Activation Events
(A) Cotransfection of CMV±CBP plasmids in
HeLa cells enhances RAR-mediated trans-
activation.
(B) Increased CBP levels potentiate hor-
mone-dependent transactivation by a GAL4±
T 3R C-term inu s fus ion prote in. In v itro
transcription assays were performed with lu-
ciferase reporters driven by 33 UAS(GAL)±tk,
human papilloma virus 16 (HPV-16) or a 12-
O-tetradecanoylphorbol-13-acetate (TPA) re-
sponse element upstream of the prolactin
minimal promoter (Drolet et al., 1991) (TRE±
p36). Increased CBP levels greatly enhanced
the TRE-driven reporter, consistent with pub-
lished results. Elevated CBP levels also in-
creased transcription of the UAS(GAL)±
tk-driven reporter by GAL4±T3R C-terminus
fusion protein in the presence of hormone. In
contrast, a viral promoter (HPV-16) containing
an Sp1 site was not activated by elevated
CBP levels.
(C) Microinjection of anti-CBP antibody abro-
gates ligand-dependent gene activation by
the RAR. Plasmids consisting of a lacZ re-
porter under the transcriptional control of
RAREs were injected into the nuclei of Rat-l
cells. RARE simian virus 40 (SV40) lacZ con-
tains three copies of the DR15 element up-
stream of the SV40 minimal promoter,
whereas the RARE±p36 lacZ contains two
copies of DR15 upstream of the prolactin
minimal promoter (Drolet et al., 1991). Each
construct was injected with preimmune IgG
(no retinoic acid [RA]) or with affinity purified
anti-CBP antibody and demonstrated a reti-
noic acid±dependent response. The expres-
sion of the reporter plasmids was monitored
by X-Gal staining and quantitated based on
the percentage of injected cells that stained
blue. Coinjection of the same anti-CBP anti-
body did not inhibit expression of the report-
ers driven by either the SV40 or CMV viral
enhancers. Photomicrographs of rhodamine-
stained injected cells (1±3) and the corre-
sponding phase-contrast picture (4±6) of
X-Gal staining show a typical result. In the
absence of retinoic acid (1 and 4), back-
ground expression of b-galactosidase is minimal. Addition of 1026 M retinoic acid (2 and 5) results in a strong transcriptional response, which
is significantly reduced in the presence of anti-CBP (3 and 6). X-Gal staining in some cells was sufficient to quench the rhodamine fluorescence
(as in 2 and 5); therefore, the number of injected cells was counted as the sum of red or blue cells. All experiments were performed at least
three separate times in which 200 or more cells were injected; error bars represent the SEM.
In addition, 32P-labeled CBP C-terminus could detect CBP-associated T3R or RAR could occur (Figure 3C;
data not shown).p160 in a biochemical interaction assay (Figure 3B).
These observations raised the possibility that RAR, CBP, cDNAs encoding the putative p160 were obtained by
expression cloning based on the criterion that phageand p160 could potentially form a ligand-dependent
complex. Because both p160 and nuclear receptors in- plaques exhibited interaction with both the CBP C-ter-
minus and liganded nuclear receptors (Figure 4). As illus-teract with distinct domains in CBP holoprotein, it was
possible to devise an assay that would unambiguously trated in Figure 4D, a series of cDNAswere identified that
encoded variant forms of the SRC-1 protein reported todemonstrate the potential simultaneous interaction of
nuclear receptors with both p160 and CBP. To achieve have a predicted molecular mass of 115 kDa (OnÄ ate et
al., 1995). The N-terminally extended variants that wethis, we used a GST fusion protein containing only the
N-terminus of CBP to bind nuclear receptors in the pres- identified included forms of 1465 and 1405 amino acids,
with predicted molecular masses of 159 and 152 kDa.ence of cellular extracts containing p160. The data
shown in Figure 3C utilized the T3R. Interacting protein This additional N-terminal sequence has revealed a ho-
mology with the A region of the PAS domain characteris-was probed on Western blots using 32P-labeled ER
C-terminus. These experiments revealed that ligand-de- tic of the PAS/helix-loop-helix (HLH) gene family (re-
viewed by Hankinson, 1995). In addition, related factorspendent simultaneous interactions between p160 and
CBP Integrator Complex in Nuclear Receptor Action
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Figure 3. Interactions between CBP and the
Nuclear Receptor±Associated p160 Coacti-
vator
(A) p160 interacts with the C-terminus of CBP.
The relative position of the CREB-binding do-
main, bromodomain, E1A, and TFIIB interac-
tion domain and the glutamine-rich region in
CBP are schematically represented. CV-1
whole-cell extracts were incubated with a se-
ries of GST±CBP fusionproteins, immobilized
on glutathione±agarose. The whole-cell ex-
tracts were also incubated with GST±RAR
C-terminus in the absence or presence of
1026 M all-trans retinoic acid. After washing,
specifically associated proteins were re-
solved by SDS±PAGE, transferred to nitrocel-
lulose, and detected using a [32P]GST±ER C-
terminus in the presence of ligand. The num-
bers at the left indicate molecular size mark-
ers (kilodaltons).
(B) Whole-cell extracts were incubated with
a ligand-treated GST±ER bound to glutathi-
one±agarose, and associated proteins were
tested for interaction as described for (A) with
either [32P]GST±ER in the presence of ligand
or [32P]GST±CBP C-terminus (amino acids
1892±2441).
(C) Nuclear receptor, CBP, and p160 can si-
multaneously form a ligand-dependent pro-
tein complex.A GST fusionprotein containing
only the N-terminus of CBP (amino acids
1±450) was incubated with bacterially ex-
pressed T3R in the presence or absence of
ligand (1026 M TRIAC) and whole-cell ex-
tracts. After washing, specifically associated
proteins were resolved by SDS±PAGE, trans-
ferred to nitrocellulose, and detected using
[32P]GST±ER in the presence of ligand as de-
scribed. The control for identification of p160
was provided by analyzing proteins from the
same whole-cell extract bound to GST±RAR
in the presence of ligand.
exhibiting z40% identity in the CBP and nuclear recep- nuclear receptor family reported by OnÄate et al. (1995),
indicating that p160 functions as a coactivator.tor interaction domains were identified (data not shown).
Antiserum raised against an internal 50 kDa region com-
mon to all the recombinant SRC-1 variant proteins was
found to interact specifically with a 160 kDa protein Both Nuclear Receptors and p160 Interact
with Conserved Motifs on CBP and p300doublet in whole-cellextracts that specifically interacted
with GST±RAR in a ligand-dependent fashion (Figure While p300 was initially described based on its interac-
tion with E1A (Eckner et al., 1994), recent data confirmed4B). Immunodepletion experiments demonstrated that
approximately 75% of the biochemically defined p160 its ability to interact with both CREB and Jun/Fos; con-
versely, CBP interactswith E1A (Arany et al., 1995; Lund-could be removed from HeLa whole-cell extracts by this
antiserum (Figure 4B), indicating that the l59 kDa variant blad et al., 1995). Although the regions of CBP found to
mediate interaction with nuclear receptors and p160of SRC-1 is the biochemically identified p160. The
N-terminus of the cloned SRC-1 protein was capable of were not initially recognized as regions of high homol-
ogy, comparison of the N- and C-terminal regions offorming a ternary complex with CBP and a liganded
nuclear receptor (Figure 4C); we have also observed CBP involved in these interactions with the correspond-
ing region of p300 revealed multiple clusters of completeassociation between SRC-1-related factors. Cotrans-
fection experiments confirmed that the SRC-1 variant identity in both the nuclear receptor interaction domain
(amino acids 1±101, CBP; amino acids 1±117, p300) andpotentiated the activity of RAR (data not shown) in con-
cert with effects of SRC-1 on several members of the in the p160 interaction domain (amino acids 2058±2163,
Cell
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Figure 4. The p160 Gene Family: Interactions with CBP and Liganded Nuclear Receptors
(A) A mouse pituitary and a human macrophage lgt11 cDNA library (Lin et al., 1992) were screened for proteins interacting with 32P-labeled
ligand-bound ER C-terminus. We identified 11 positive plaques from 1.5 3 106 plaques evaluated, 7 of which also interacted with the
[32P]GST±CBP C-terminus (amino acids 2058±2163).
(B) p160 is antigenically related to SRC-1. A guinea pig polyclonal antiserum was raised against a GST fusion of a 500 amino acid region
common to all SRC-1 variants, encompassing the nuclear receptor and CBP interaction domains. This antiserum was used to immunodeplete
reactive proteins from HeLa whole-cell extracts (lanes 3 and 7). Preimmune serum was used as a control (lanes 4 and 8). Treated and untreated
whole-cell extracts were incubated with GST±RAR bound to glutathione±agarose, in the presence or absence of all-trans retinoic acid, to
purify putative coactivator proteins. Following extensive washing, specifically bound proteins and GST±RAR were resolved by SDS±PAGE
and transferred to a nitrocellulose membrane. The membrane was first probed with liganded [32P]GST±ER to detect p140 and p160 (lanes 2
and 6). Pretreatment of HeLa extracts with SRC-1 antiserum, but not preimmune serum, resulted in a marked decrease in the p160 band
detected by labeled ER (compare lanes 2 and 3). The membrane was then stripped and probed with anti-SRC-1 IgG. This demonstrated near
quantitative (>75%) removal of the p160 recognized by specific antisera during the initial immunodepletion (compare lanes 6 and 7).
(C) Nuclear receptors, CBP, and SRC-1 can form a ligand-dependent ternary protein complex. A protein±protein interaction assay was
performed with GST±CBP (1±450), which contains only the nuclear receptor interaction domain, bacterially expressed His±T3R, and in vitro
translated 35S-labeled SRC-1 in the absence or presence of 1026 M TRIAC (lanes 2 and 3). GST alone was used as a negative control (lane
1), and 25% of SRC-1 input is shown (lane 4).
(D) A mouse cDNA encoding a 159 kDa variant of SRC-1. Sequencing of murine and human cDNA isolates revealed an open reading frame
predicting a protein of 1465 amino acids, containing an N-terminal extension beyond the sequence of human SRC-1 (OnÄ ate et al., 1995) with
CBP Integrator Complex in Nuclear Receptor Action
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activation of AP-1-dependent promoters. If competition
for limiting quantities of CBP accounts for the inhibitory
effect of nuclear receptors, then increased levels of CBP
should restore AP-1-dependent activation. Indeed, the
inhibitory effects of liganded RAR and GR were largely
or completely abolished by cotransfection of vectors
expressing CBP (Figure 6A). Cotransfection with vectors
expressing p300 also diminished the AP-1 inhibitory ef-
fects of nuclear receptors, but appeared somewhat less
effective than CBP (Figure 6A). Mutations in the RAR AF2
domain that inhibit binding of CBP and other coactivator
proteins abolished AP-1 repression by nuclear recep-
tors, consistent with previous data involving C-terminal
receptor deletions (Desbois et al.,1991; Saatciogluet al.,
1994) (data not shown). The CBP-dependent inhibition of
AP-1 activity could formally reflect either an allosteric
effect whereby binding of nuclear receptors could pre-
clude binding of the AP-1 complex to CBP or a competi-
tion for limiting amounts of CBP. However, the first pos-
sibility appears unlikely because we found that binding
of nuclear receptors (RAR) and Jun could simultane-
ously occur on CBP (data not shown).
A recently described synthetic RAR ligand (LG550)
exerts a potent anti-AP-1 effect, while LG629 serves as
an antagonist (Figure 6B). Based on the model that CBP
partitioning can mediate trans-repression of AP-1 by
nuclear receptors, it would be predicted that LG550
might result in potent association with CBP. This possi-Figure 5. p300 Interacts with Nuclear Receptors and p160
bility was initially assessed using GST±RAR fusion pro-(A) Comparison of the N- and C-terminal regions of CBP involved
in nuclear receptor and p160 interactions with the corresponding teins, which revealed significantly enhanced binding of
region of human p300. Black background indicates identical res- CBP N-terminus in the presence of LG550 compared
idues.
with all-trans retinoic acid, while interaction was abol-(B) Interaction between the N-terminus of p300 (amino acids 1±117)
ished by the antagonist, LG629. Further, using the yeastand CBP (amino acids 1±101) with RARa C-terminus was assessed
two-hybrid assay, LG550 was found to be a more potentusing the yeast two-hybrid assays as described in the legend to
Figure 1B. stimulator of CBP±RAR interactions than all-trans reti-
(C) p300 (amino acids 2042±2160) and CBP (amino acids 2058±2162) noic acid, while LG629 abolished interaction (data not
were expressed as GST fusion proteins, bound to glutathione±
shown). Finally, interactions in intact cells were as-agarose, and incubated with whole-cell extracts. After washing,
sessed by immunoprecipitation of CBP-containing com-specifically associated proteins were resolved by SDS±PAGE, trans-
plexes after addition of various ligands. As shown inferred to nitrocellulose, and then detected using [32P]GST±ER in the
presence of ligand as described for Figure 1A. The numbers at the Figure 6B, CBP±RAR interactions were markedly in-
left indicate molecular size markers. creased when LG550 was added compared with cells
treated with all-trans retinoic acid, and the interaction
was abolished by LG629. Together, these observationsCBP; amino acids 2042±2157, p300) (Figure 5). Consis-
are consistent with the hypothesis that the interactiontent with these sequence homologies, the N-terminus
between RAR and CBP is responsible for some formsof p300 interacted with the RAR in a ligand-dependent
of repression of AP-1 activity. If this were the case, onemanner, while its C-terminus interacted with p160 (Fig-
would predict that CREB, which appears to have a veryure 5). The strength of these interactions was compara-
high affinity for CBP, might be able actually to inhibitble to those of the corresponding regions of CBP.
nuclear receptor activation. This possibility was tested
by transfection of a RARE-dependent reporter andRole of CBP in Nuclear Receptor±Mediated
cytomegalovirus (CMV)±CREB and retinoic acid±depen-Inhibition of AP-1 Activity
dent induction after treatment of cells with 8-bromo-In parallel, we wished to explore a potential role for
cAMP. Indeed, activated CREB reduced retinoic acid±CBP in mediation of ligand-dependent inhibition of AP-1
dependent stimulation from .40-fold to z5-fold (Figurefunction. To begin to test this hypothesis, we estab-
6C), without affecting the basal activity of the RARE-lished a transfection assay in which liganded RAR or GR
could effectively inhibit (z80%) phorbol ester±mediated driven reporter.
high homology (z88% identity) over the rest of SRC-1. Additional variants of SRC-1 with distinct N-terminal (SRC-1b) or C-terminal sequences
(SRC-1c and SRC-1d) reflecting alternative splicing events were detected.
(E) Homology between an N-terminal region of p160 and the A region of the PAS domain of PAS/bHLH proteins.
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Figure 6. Role of CBP in trans-Repression of
AP-1 by Nuclear Receptors
(A) Increased expression of CBP or p300 ab-
rogates RAR- and GR-mediated repression
of AP-1 activation in HeLa cells. Fold induc-
tion of the reporters by TPA was plotted. Both
RAR and GR exhibited ligand-dependent re-
pression of TPA-stimulated transcription of a
promoter containing an AP-1 site. Induction
by TPA was z80% repressed by retinoic acid
(1027 M) or dexamethasone (1027 M). The inhi-
bition by retinoic acid was largely decreased
or abolished when plasmids expressing ei-
ther a CBP or p300 transcription unit were
cotransfected (lower left). In a similar fashion,
the repression by liganded GR was alleviated
with cotransfection of CBP and partially re-
covered with overexpression of p300 (lower
right).
(B) LG550 enhances interactions between
RAR and CBP. Whole-cell extracts were pre-
pared from 293 cells expressing FLAG±CBP
and immunoprecipitated with RAR antibody
(HoÈ rlein et al., 1995) in the presence or ab-
sence of all-trans retinoic acid, LG550, or
LG629 (1027 M). Western blot analysis was performed using anti-FLAG antibody. Transient transfection experiments similar to that described
in (A) were done with LG550 and LG629 at two concentrations. Activity in the absence of ligand was arbitrarily defined as 100%.
(C) Effects of overexpression of CREB on retinoic acid±stimulated gene expression. Increased CREB levels led to reduced retinoic acid
stimulation of RARE-driven reporter in HeLa cells. Thus, the z45-fold induction of the reporter by retinoic acid was gradually reduced to z5-
fold with increasing amounts of CMV±CREB cotransfected. In all cases, 8-bromo-cAMP (1 mM) was administered together with retinoic acid
(1027 M) to activate both pathways at the same time. The baseline expression of the reporter in the absence of retinoic acid and cAMP
remained constant with increasing amount of cotransfected CREB. Similar results were obtained in P19 cells.
Discussion cells, such as HeLa cells, containing little p140 (Figure
4), our observations suggest that transcriptional activa-
tion by nuclear receptors is mediated by a complexCoactivator Complexes in Nuclear
Receptor Transactivation Events that contains both CBP and p160 and probably other
components. We have presented evidence that p160Based on the data presented in this manuscript, we
have found, unexpectedly, that CBP/p300 appear to be represents a major form of a family of SRC-1-related
proteins. Because CBP can interact independently withrequired for effective ligand-dependent gene activation
by nuclear receptors. A crucial role of CBP in ligand- nuclear receptors, p160, and the related family mem-
bers, it is likely that interactions between these proteinsdependent activation events is supported by the obser-
vations that ligand-dependent association between are involved in transactivation events. Thus, one func-
tion of a nuclear receptor coactivator, such as p160,CBP and nuclear receptors occurs both in intact cells
and on DNA-bound receptor complexes and that anti- could be to increase the specificity and strength of inter-
action of nuclear receptors with members of the CBPCBP antibodies selectively inhibit the transcriptional ac-
tivities of nuclear receptors in intact cells. Furthermore, family, potentially providing a direct link to the core
transcriptional machinery (Drapkin et al., 1993), analo-increased levels of CBP selectively permit thyroid hor-
mone±dependent transcription in vitro, indicating that gous to the independent contacts proposed in syner-
gistic interactions between transcription factors boundthis factor is rate limiting in nuclear extracts. Thus, the
identical criteria that have linked CBP to transactivation to distinct DNA sites (Hansen and Tjian, 1995). The exis-
tence of CBP and p300, and of multiple SRC-relatedby CREB and Jun/Fos (Arias et al., 1994; Kwok et al.,
1994) have been fulfilled for ligand-dependent gene acti- nuclear receptor coactivators, provides a potential com-
binatorial code for imparting receptor, DNA site, andvation, indicating that CBP plays a comparable role in
nuclear receptor transactivation events. polarity specificity. The presence of a canonical bromo-
domain in CBP and p300, but not in p160/SRC-1 factors,While these surprising results implicate members of
the CBP/p300 family as required for transcriptional acti- suggests that a component of the requirement for CBP/
p300 might reflect actions on chromatin structure com-vation by nuclear receptors, they are not likely alone to
be sufficient. A series of additional potential nuclear parable with the actions proposed in SWI/SIN control of
gene expression (e.g., Peterson and Herskowitz, 1992;receptor coactivators have been identified and reported
(Cavailles et al., 1994; Halachmi et al., 1994; Lee et al., Winston and Carlson, 1992).
1995; Le Dourain et al., 1995; OnÄate et al., 1995) that
require a specific C-terminal domain (AF2) that plays Partitioning of CBP/p300 in AP-1 Inhibition
by Nuclear Receptorsa structural role in configuring the receptor C-termini
(Bourguet et al., 1995; Renaud et al., 1995; Wagner et The identification of CBP as an integral component of
the activation complex for nuclear receptors obviouslyal., 1995). Because nuclear receptors function well in
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can be abolished by raising the levels of CBP, regulation
of CBP expression is likely to be of critical importance
in determining the transcriptional consequences of si-
multaneous activation of multiple pathways. Indeed, evi-
dence that CBP is physiologically maintained at a
limiting concentration is strongly suggested by the ob-
servation that individuals heterozygous for a truncated
CBP transcription unit exhibit severe developmental de-
fects, the Rubinstein±Taybi syndrome (Petrij et al.,
1995).
The observation that the interaction of CBP with nu-
clear receptors not only involves a direct contact with
the nuclear receptor ligand-binding domain, but also a
simultaneous interaction with p160, suggests that com-
parable coactivators will be required for other classes
of transcription factors. For example, studies of CREB
have indicated that, while necessary, interaction with
Figure 7. CBP/p300 Function as Cointegrators of Diverse Signaling
CBP is not sufficient for transcriptional activation. InPathways
addition to phosphorylation of Ser-133 of CREB, whichBoth nuclear receptors and targets of plasma membrane receptors,
permits CBP interaction, an additional domain, referredincluding Jun, Fos, and CREB, associate with the CBP/p300 family.
to as Q2, is required for functional activity (Brindle etIn the case of nuclear receptor heterodimers, such as RXR and
RAR, liganded RAR associates with nuclear receptor coactivators al., 1993). These observations suggest the existence of
(N-CoA), including variant forms of SRC-1, which recruit CBP into the a CREB coactivator that is distinct from p160 (unpub-
complex.CBP/p300 servesas thecointegrator, partitioning between lished data), but functions in an analogous manner
AP-1, nuclear receptor heterodimers, and other factors, accounting,
(Figure 7).at least in part, for antagonistic relationships between diverse signal
Analysis of the N-terminal sequence of the p160 pro-transduction pathways.
tein reveals that it contains a region that is homologous
to the PAS domain of the growing family of PAS/basic±
suggests a molecular mechanism by which nuclear re- helix-loop-helix (bHLH) factors (Hankinson, 1995). This
ceptors might inhibit AP-1 action, based on a require- family includes the dioxin receptor and hypoxia-induc-
ment for the relatively low intracellular levels of the CBP/ ible factor, which bind as heterodimers with ARNT to
p300 family proteins by both classes of transcription
asymmetric DNA response elements. The PAS domain
factors. Because increasing the intracellular levels of
is established to be a bipartite dimerization interface,
this family of coactivators serves to abolish RAR or GR
suggesting an intriguing linkage of p160/CBP integration
repression of AP-1, and because AP-1 can effectively
to a second, structurally distinct family of heterodimeric
bind to RAR-associated CBP, it is likely that the limiting
transcription factors, of which at least one is ligand
amount of the CBP family factors is partitioned by the
regulated. Further, these HLH factors may directly inter-
alternative activation of nuclear receptors by ligand, or
act with CBP, completing the parallel to nuclear recep-
of AP-1 by phosphorylation. Although a competition
tors. Thus, the same integrator complex partners maymodel provides a mechanism for the observed antago-
mediate transactivation by nuclear receptors and PAS/nism between nuclear receptors and AP-1 on genes that
HLH factors.contain binding sites for only one class of factor, they do
We propose that the CBP/coactivator complexes benot account for the more complex pattern of regulation
referred to as ªintegratorsº based on their role in de-observed for genes containing composite response ele-
termining the relative transcriptional responses of a spe-ments, as studied most extensively in the case of the
cific target gene in the face of activation of multipleproliferin gene (Lefstin et al., 1994). In this case, nuclear
signaling pathways. The relative abilities of coactivatorsreceptors and AP-1 protein can act either cooperatively
to recruit limiting amounts of CBP into integrator com-or antagonistically, depending upon the identity and
plexes could account for aspects of the multifactorialconformation of the nuclear receptor (i.e., GR or mineral-
control of biological processes underregulation of multi-ocorticoid receptor) and AP-1 complex (Jun/Jun or Jun/
ple signal transduction pathways. Thus, the precise co-Fos) bound to the composite element. It is possible that
hort of genes activated in a given cell will depend onon such an element, some combinations of coactivators
both the relative activity of diverse signaling pathwayspromote, while others inhibit, the recruitment of CBP.
and the organization and relative affinity of the complex
on various DNA-bound factors that utilize CBP as aThe CBP/p300 Family as Functional Integrators
coactivator (see Figure 7). Synergy might be expectedof Diverse Signal Transduction Pathways
on some promoters, while competitive interaction wouldThe demonstration that CBP is required for transcrip-
be expected for others that contain only a subset oftional activation by CREB, AP-1, and nuclear receptors,
sites for interacting transcription factors. Thereby, theand that these factors compete with each other to inter-
CBP/p300 family serves to integrate the signals of di-act with limiting amounts of CBP within the cell, sug-
verse growth factors, hormones, and intracellular li-gests that CBP functions as a nuclear integrator of multi-
gands that combinatorially modulate homeostasis andple signal transduction pathways (Figure 7). Because
the antagonistic effects of nuclear receptors and AP-1 proliferation.
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Experimental Procedures constructed from human macrophage and mouse pituitary libraries,
as described (Vinson et al., 1988).
Yeast Two-Hybrid Assay and Interaction Assays
Yeast strain EGY48, the LexA±b-galactosidase reporter construct Immunoprecipitation
(pSH18-34), and the LexA and B42 parental vectors (pEG202 and EBNA cells (293) were transfected with pCEP4 CBP containing a
pJG4-5) were as reported previously (Gyuris et al., 1993). PCR frag- C-terminal in-frame FLAG epitope, (EYKEEEK)2. Where required,ments of rat T3Ra1 (122±410 and E403Q), human RARa (143±462 RSV-RAR or GR was cotransfected. Immunoprecipitation and de-
and 143±403; D403 and G303E), mouse RXRg (227±463 and E454Q), tection wereperformed as previously described (HoÈ rlein et al., 1995).
and human ER (251±595) were subcloned into pEG202 bait vector.
cDNA encoding the CBP holoprotein was isolated from a mouse
Acknowledgmentspituitary cDNA library (Lin et al., 1992). DNA fragments encom-
passing the entire CBP protein were subcloned into the pJG4±5
The first four authors have contributed critical independent aspects,prey vector. b-Galactosidase activity was determined as described
permitting presentation of an integrated study. We also acknowl-previously (Ausubel et al., 1994). Ligands used in the yeast two-
edge Peng Li for her contributions, Marcus Boehm for developmenthybrid assays were 1027 M TRIAC for T3R, 1027 M TTNPB for RAR,
of synthetic ligands, David Livingston for the p300 cDNA clone,1027 M LG69 for RXR, and 1027 M b-estradiol for ER. Protein±protein
Tina-Marie Mullen for excellent technical assistance, Mathias Treierinteraction assays using GST fusion proteins were performed as
for critical review, and Beth Stawiarski for help in preparation ofpreviously described (HoÈ rlein et al., 1995). For gel mobility shift
the manuscript. D. W. R. is supported by an American Diabetesassays, oligonucleotides containing the consensus CREB-binding
Association Career Development Award, J. T. by the Medical Re-site (59-AGAGATTGCCTGACGTCAGAGAGCTAG-39) or the DR15
RARE (59-TCGACGAAGGGTTCACCGAAAGTTCACTCGCG-39) were search Council of Canada, and T. H. by the Deutsche Forschungs-
labeled with 32P using T4 polynucleotide kinase (New England Bi- gemeinschaft and the University of California Breast Cancer Re-
olabs). search Program. M. G. R. is an Investigator with the Howard Hughes
Medical Institute. These studies were supported by grants from the
In Vitro Transcription, Transient Transfections, National Institutes of Health to C. K. G. and M. G. R.
and Reporter Assays
The cell-free transcription reaction with nuclear extractswas carried Received February 14, 1996; revised March 27, 1996.
out as described previously (Gloss and Bernard, 1990). Where indi-
cated, 100 ng of purified His±GAL4±human T3Rb protein (amino Referencesacids 1±147 of GAL4 fused to amino acids 165±456 of T3Rb) was
added to the reaction prior to addition of nuclear extract. Templates Abate, C., and Curran, T. (1990). Encounters with Fos and Jun on
were 300 ng of 33 GAL4±tk luciferase (HoÈ rlein et al., 1995), 50 ng the road to AP-1. Semin. Cancer Biol. 1, 19±26.
of HPV-16 luciferase (Gloss and Bernard, 1990) or 100 ng of AP-
Angel, P., and Karin, M. (1991). The role of Jun, Fos and the AP-11±p36 luciferase per reaction. Primer extension was carried out
complex in cell-proliferation and transformation. Biochim. Biophys.with SuperScript RNaseH2 (GIBCO BRL) and the 32P labeled primer
Acta 1072, 129±157.CCAGGAACCAGGGCGTATCTCTTCATAGCC. For studying AP-1 re-
pression by nuclear receptors, 2±4 hr before transfection the me- Arany, Z., Sellers,W.R., Livingston,D.M., and Eckner, R. (1994). E1A-
dium, calf serum, was replaced with DMEM containing 10% char- associated p300 and CREB-associated CBP belong to a conserved
coal-stripped serum. Plasmid DNAs were transfected into HeLa cells family of coactivators. Cell 77, 799±800.
with standard calcium phosphate precipitation procedure (Gorman Arany, Z., Newsome, D., Oldread, E., Livingston, D.M., and Eckner,
et al., 1982). Typically, 1 mg of TRE-driven reporter, 1 mg of RSV- R. (1995). A family of transcriptional adaptor proteins targeted by
RXRa or GR, and 2 mg of CMV±CBP or CMV±p300 were used, the the E1A oncoprotein. Nature 374, 81±84.
final DNA concentration was adjusted to 5 mg per 60 mm dish, and
Arias, J., Alberts, A.S., Brindle, P., Claret, F.X., Smeal, T., Karin, M.,TPA (Sigma) was administered at a final concentration of 100 ng/
Feramisco, J., and Montminy, M. (1994). Activation of cAMP andml in the presence or absence of all-trans retinoic acid, LG550,
mitogen responsivegenes relieson a common nuclear factor. NatureLG629, or dexamethasone at indicated concentrations.
370, 226±229.
Nuclear Microinjection, Staining, Ausubel, F.M., Brent, R., Kingston,R.E., Moore, D.D., Seidman, J.G.,
and Fluorescence Microscopy Smith, J.A., and Struhl, K. (1994). Current Protocols in Molecular
Insulin-responsive Rat-1 fibroblasts were seeded on acid-washed Biology (New York: Greene Publishing Association).
glass coverslips at subconfluent density and grown in MNE/F12 Baniahmad, A., Leng, X., Burris, T.P., Tsai, S.Y., Tsai, M.J., and
medium supplemented with 10% fetal bovine serum, gentamicin, O'Malley, B.W. (1995). The tau4 activation domain of the thyroid
and methotrexate. Prior to the injection, the cells were rendered
hormone receptor is required for release of a putative corepressor(s)
quiescent by incubation in serum-free medium for 24±36 hr. Plas-
necessary for transcriptional silencing. Mol. Cell. Biol. 15, 76±86.
mids were injected into the nuclei of cells at a final concentration
Bannister, A.J., and Kouzarides, T. (1995). CBP-induced stimulationof 100 mg/ml. Either preimmune rabbit IgG or anti-CBP antibody
of c-Fos activity is abrogated by E1A. EMBO J. 14, 4758±4762.(Santa Cruz Biotechnology) was coinjected and allowed the unam-
biguous identification of the injected cells. Microinjections were Beato, M., Herrlich, P., and SchuÈ tz, G. (1995). Steroid hormone re-
carried out using an Eppendorf semiautomated microinjection sys- ceptors: many actors in search of a plot. Cell 83, 851±857.
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with tetramethylrhodamine-conjugated donkey anti-rabbit IgG. Bugge, T.H., Pohl, J., Lonnoy, O., and Stunnenberg, H.G. (1992).
Cells were viewed andthe results were analyzed on a Zeiss Axiophot RXRa, a promiscuous partner of retinoic acid and thyroid hormone
microscope. Photomicrographs were taken with the same equip- receptors. EMBO J. 11, 1409±1418.
ment using Kodak Ektachrome 400 color film.
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